Premium
Predictive value of venom‐specific IgE, IgG and IgG subclass antibodies in patients on immunotherapy with honey bee venom
Author(s) -
MÜLLER U.,
HELBLING A.,
BISCHOF M.
Publication year - 1989
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/j.1398-9995.1989.tb04172.x
Subject(s) - subclass , immunoglobulin e , sting , immunology , antibody , medicine , immunotherapy , allergy , honey bee , venom , immunoglobulin g , biology , immune system , ecology , engineering , aerospace engineering
Sixty‐seven patients with a history of severe systemic reactions following honey bee stings were treated by immunotherapy (IT) with honey bee venom. During maintenance therapy all were submitted to a sting challenge under clinical conditions. 15 developed mostly minor symptoms of a systemic reaction while 52 showed only a local swelling at the sting site. Phospholipase A 2 ‐specific IgE, IgG and IgG subclass serum antibodies were estimated in samples obtained before IT and immediately before the challenge. Specific IgE decreased in reactors and in non‐reactors. There was no difference between the two groups at any time. Specific total IgG, IgG 1 and IgG 4 increased in both reactors and non‐reactors during IT. An early increase of specific IgG 1 , was observed while specific IgG 4 remained elevated throughout the treatment. Specific total IgG was higher in reactors than non‐reactors before the challenge, specific IgG 1 higher in reactors before treatment and specific IgG 4 higher in reactors than non‐reactors both before treatment and before challenge. In the individual patient, no single antibody estimation or combination of various antibodies was predictive of the outcome of a sting challenge.